From: Evidence for harm reduction in COPD smokers who switch to electronic cigarettes
Baseline | 12-Month Follow-up | Within group p value vs BaselineΩ | 24-Month Follow-up | Within group P value vs BaselineΩ | Overall between group p value from Baselineƙ | |
---|---|---|---|---|---|---|
COPD Controls (n = 24) | ||||||
post-BD FEV1a (L) | 1.47 (1.13, 1.72) | 1.43 (1.12, 172) | 0.538 | 1.45 (1.17, 1.66) | 0.657 | 0.223 |
post-BD FVCa (L) | 2.39 (2.1, 2.64) | 2.35 (2.2, 2.74) | 0.065 | 2.35 (2.19, 2.83) | 0.141 | 0.977 |
%FEV1/FVCb | 56.2 (±10.3) | 55.9 (±10.1) | 0.328 | 56.3 (±10.1) | 0.277 | 0.033 |
Cig/dayb | 20.5 (±3.3) | 20.1 (±3.7) | 0.371 | 19.8 (±5) | 0.296 | <0.001 |
CAT scorea | 20.5 (17.8, 24.3) | 20 (17.5, 24.3) | 0.075 | 20 (15.8, 24) | 0.361 | 0.001 |
COPD Exacerbationsb | 2.1 (±1.1) | 2.2 (±1) | 0.906 | 2.1 (±1.1) | 0.819 | 0.005 |
6MWDa, c | 267.3 (195, 351.5) | 270 (210.3, 372) | 0.056 | 270.5 (220.8, 373.9) | 0.096 | 0.002 |
COPD EC users (n = 24) | ||||||
post-BD FEV1a (L) | 1.25 (0.94, 1.78) | 1.23 (0.93, 1.73) | 0.102 | 1.29 (0.92, 1.67) | 0.153 | |
post-BD FVCa (L) | 2.37 (2, 2.65) | 2.45 (1.92, 2.73) | 0.081 | 2.46 (1.84, 2.86) | 0.252 | |
%FEV1/FVCb | 59.4 (±8.4) | 58.3 (±8.6) | 0.457 | 57.9 (±8.5) | 0.483 | |
Cig/dayb | 21.8 (±4.4) | 1.8 (±2.2) | <0.001 | 1.58 (±2) | <0.001 | |
CAT scorea | 21.5 (17.8, 25.3) | 17.5 (15.8, 20.5) | <0.001 | 18 (15, 20) | <0.001 | |
COPD Exacerbationsb | 2.3 (±1) | 1.8 (±1) | 0.002 | 1.4 (±0.9) | <0.001 | |
6MWDa, c | 266.5 (187.5, 313.5) | 307 (219.5, 342) | 0.002 | 327 (239.5, 359.5) | 0.002 |